CA2829586C - Methods and compositions relating to mesenchymal stem cell exosomes - Google Patents

Methods and compositions relating to mesenchymal stem cell exosomes Download PDF

Info

Publication number
CA2829586C
CA2829586C CA2829586A CA2829586A CA2829586C CA 2829586 C CA2829586 C CA 2829586C CA 2829586 A CA2829586 A CA 2829586A CA 2829586 A CA2829586 A CA 2829586A CA 2829586 C CA2829586 C CA 2829586C
Authority
CA
Canada
Prior art keywords
exosomes
isolated
composition
msc exosomes
msc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2829586A
Other languages
English (en)
French (fr)
Other versions
CA2829586A1 (en
Inventor
S. Alexander Mitsialis
Changjin Lee
Stella KOUREMBANAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Children's Hospital
Original Assignee
Boston Children's Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Children's Hospital filed Critical Boston Children's Hospital
Publication of CA2829586A1 publication Critical patent/CA2829586A1/en
Application granted granted Critical
Publication of CA2829586C publication Critical patent/CA2829586C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0082—Lung surfactant, artificial mucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
CA2829586A 2011-03-11 2012-03-09 Methods and compositions relating to mesenchymal stem cell exosomes Active CA2829586C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161451981P 2011-03-11 2011-03-11
US61/451,981 2011-03-11
PCT/US2012/028524 WO2012125471A1 (en) 2011-03-11 2012-03-09 Methods and compositions relating to mesenchymal stem cell exosomes

Publications (2)

Publication Number Publication Date
CA2829586A1 CA2829586A1 (en) 2012-09-20
CA2829586C true CA2829586C (en) 2021-03-02

Family

ID=45852770

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2829586A Active CA2829586C (en) 2011-03-11 2012-03-09 Methods and compositions relating to mesenchymal stem cell exosomes

Country Status (8)

Country Link
US (3) US9901600B2 (enExample)
EP (1) EP2683389B1 (enExample)
JP (2) JP6204830B2 (enExample)
KR (2) KR102063069B1 (enExample)
CN (2) CN103648509B (enExample)
CA (1) CA2829586C (enExample)
ES (1) ES2629502T3 (enExample)
WO (1) WO2012125471A1 (enExample)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
KR102063069B1 (ko) * 2011-03-11 2020-01-08 칠드런'즈 메디컬 센터 코포레이션 중간엽 줄기 세포 엑소솜에 관련된 방법 및 조성물
ITRM20110403A1 (it) 2011-07-28 2013-01-29 Ospedale Pediatrico Bambino Gesu Microvescicole isolate da cellule mesenchimali come agenti immunosoppressori.
US9427450B2 (en) * 2012-01-31 2016-08-30 Xon Cells, Inc. Therapeutic immune modulation by stem cell secreted exosomes
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
EP3563859B1 (en) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
CN103865873B (zh) * 2012-12-12 2017-04-05 中国医学科学院基础医学研究所 亚全能干细胞分泌的外来体及其应用
CA2893951C (en) * 2012-12-12 2022-05-03 Mesoblast, Inc. Methods of treating or preventing respiratory conditions
RU2644247C2 (ru) 2013-03-15 2018-02-08 Борд оф Риджентс, Дзе Юниверсити оф Тексас Систем Использование биогенеза микрорнк в экзосомах для диагностики и лечения
AU2014275130B2 (en) 2013-06-05 2019-09-12 Reverse Bioengineering, Inc. Compositions and methods for induced tissue regeneration in mammalian species
US20160199413A1 (en) * 2013-08-01 2016-07-14 Isletone Ab Mscs in the treatment of inflammatory pulmonary diseases
GB201317887D0 (en) 2013-10-09 2013-11-20 Reneuron Ltd Product
CN104694466A (zh) * 2013-12-06 2015-06-10 山西医科大学 间充质干细胞来源的胞外体制备及在急性肺损伤中的应用
US10167448B2 (en) 2013-12-12 2019-01-01 Samsung Life Public Welfare Foundation Pharmaceutical composition for treating cerebrovascular diseases, containing stem cell-derived exosome as active ingredient
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
WO2015142061A1 (ko) 2014-03-18 2015-09-24 사회복지법인 삼성생명공익재단 줄기세포 유래 엑소좀을 유효성분으로 포함하는 뇌 염증성 질환의 치료용 조성물
DK3145493T3 (da) * 2014-05-18 2022-10-31 Childrens Medical Center Fremgangsmåder og sammensætninger vedrørende exosomer
US20170112879A1 (en) * 2014-06-09 2017-04-27 University Of Washington Methods of protection against ischemia reperfusion injury
KR102213527B1 (ko) * 2014-06-30 2021-02-09 타이제닉스, 에스.에이.유. 패혈증 치료용 중간엽 기질세포
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
EP3209768A1 (en) 2014-07-25 2017-08-30 Recellerate Inc. Methods of treating exercise-induced pulmonary hemorrhage
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
US20170304368A1 (en) * 2014-10-06 2017-10-26 Cedars-Sinai Medical Center Polarization of macrophages to a healing phenotype by cardiosphere-derived cells and by the exosomes secreted by such cells
CN111773173B (zh) 2014-11-07 2024-03-22 胞外体干细胞株式会社 用于成脂分化诱导、脂肪组织再生、皮肤美白或改善皱纹的包含干细胞来源外泌体的组合物
WO2016072821A1 (ko) * 2014-11-07 2016-05-12 한양대학교 에리카산학협력단 줄기세포 유래 엑소좀을 함유하는 지방세포 분화유도, 지방조직 재생, 피부 미백 또는 주름개선용 조성물
US20160158291A1 (en) * 2014-12-03 2016-06-09 Capricor, Inc. Processes for producing stable exosome formulations
CN104560877B (zh) * 2014-12-18 2017-07-28 福州市传染病医院 一种快速分离细胞外吐小体的方法
EP3239292A4 (en) * 2014-12-24 2018-09-05 Ube Industries, Ltd. Cell culture supernatant fluid derived from lung tissue
WO2016111899A1 (en) * 2015-01-05 2016-07-14 Petrucci Gary M Methods and materials for treating lung disorders
US9687511B2 (en) 2015-03-06 2017-06-27 Vivex Biomedical, Inc. Acellular biologic composition and method of manufacture
US11160904B2 (en) * 2017-05-09 2021-11-02 Vivex Biologies Group, Inc. Biological composition in a protectant shroud and methods
US20180325830A1 (en) 2017-05-09 2018-11-15 Vivex Biomedical, Inc. Coated biological composition
KR101566450B1 (ko) * 2015-04-03 2015-11-05 (유)스템메디케어 중간엽 줄기세포에서 단백질의 대량 생산 방법
MX2017013852A (es) * 2015-04-28 2019-04-15 Texas A & M Univ Sys Produccion escalable de vesiculas extracelulares estandarizadas, preparaciones de vesiculas extracelular y usos de estos.
EP3308158A4 (en) 2015-06-10 2018-12-05 Children's National Medical Center Adipocyte-derived exosomes, and compositions, kits, and methods of using the same for detection and screening
EA201890006A1 (ru) * 2015-06-10 2018-05-31 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Применение экзосом для лечения болезни
US11123376B2 (en) * 2015-06-12 2021-09-21 Monash University Method of treatment
US11077147B2 (en) * 2015-07-20 2021-08-03 Vivex Biologics Group, Inc. Acellular biologic composition and method of manufacture
HRP20230865T1 (hr) * 2015-07-31 2023-11-10 Exotropin, Llc Kompozicije egzosoma i postupci za njihovu pripremu i primjenu za reguliranje i kondicioniranje kože i kose
CN115433707A (zh) 2015-12-07 2022-12-06 再生疗法有限公司 用于重新衍生不同的多能干细胞衍生的褐色脂肪细胞的方法
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US11918687B2 (en) * 2016-01-15 2024-03-05 Orbsen Therapeutics Limited SDC-2 exosome compositions and methods of isolation and use
EP3407844A4 (en) 2016-01-29 2019-10-16 Qool Therapeutics, Inc. AEROSOLISATION OF STEM CELLS OR STEM CELL DERIVATIVES FOR PULMONARY ADMINISTRATION
KR101843634B1 (ko) 2016-04-15 2018-03-30 사회복지법인 삼성생명공익재단 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 만성폐질환 치료용 조성물
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
US10946047B2 (en) * 2016-06-17 2021-03-16 United Therapeutics Corporation Extracellular vesicles with enhanced potency
JP2019518049A (ja) * 2016-06-17 2019-06-27 ユナイテッド セラピューティクス コーポレイション 高い効能を有する細胞外小胞
CA3032925A1 (en) * 2016-08-03 2018-02-08 Life Science Institute, Inc. Alleviation and treatment of ischemia reperfusion-induced lung injury using pluripotent stem cells
SG11201900983TA (en) * 2016-08-03 2019-03-28 Univ Nagoya Nat Univ Corp Amelioration and treatment of chronic lung disease using pluripotent stem cells
KR101830290B1 (ko) * 2016-08-05 2018-02-21 한양대학교 에리카산학협력단 지방 유래 줄기세포로부터 추출된 엑소좀을 유효성분으로 포함하는 폐 섬유증 예방 또는 치료용 조성물
WO2018057542A1 (en) 2016-09-20 2018-03-29 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
EP3525801A1 (en) * 2016-10-13 2019-08-21 VBC Holdings LLC Medical uses of exosomes
WO2018071682A1 (en) * 2016-10-13 2018-04-19 Vbc Holdings Llc Anti-inflammatory exosomes from inflamed cells or tissues
DK3589298T3 (da) * 2017-02-28 2022-09-26 Univ De Lorraine Mesenkymale stamceller udvundet af wharton-gelé til behandling af sepsis
WO2018187686A1 (en) * 2017-04-07 2018-10-11 StemoniX Inc. Method of manufacturing and purifying exosomes from non-terminally differentiated cells
EP3612191B1 (en) 2017-04-19 2026-03-11 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
US11692172B2 (en) * 2017-06-26 2023-07-04 Mackay Memorial Hosptal Formulation comprising extracellular vesicles, method for producing the same, and uses thereof
AU2018297313A1 (en) 2017-07-06 2020-02-20 Children's National Medical Center Exosomes and methods of use thereof
KR20190011213A (ko) * 2017-07-24 2019-02-01 한양대학교 에리카산학협력단 줄기세포로부터 추출된 엑소좀을 유효성분으로 포함하는 골다공증 예방 또는 치료용 조성물
AU2018316603B2 (en) 2017-08-15 2024-06-13 Children's Medical Center Corporation Purified mesenchymal stem cell exosomes and uses thereof
US11471559B2 (en) 2017-11-20 2022-10-18 Vivex Biologics Group, Inc. Bioenergetic bone
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
WO2019217091A1 (en) 2018-04-30 2019-11-14 Children's Medical Center Corporation Mesenchymal stromal cell exosomes and uses thereof
WO2019212305A1 (ko) * 2018-05-04 2019-11-07 사회복지법인 삼성생명공익재단 기관지 폐 이형성증 (bpd) 예방 또는 치료용 물질 스크리닝 방법
EP3801028A4 (en) 2018-05-30 2022-04-13 Direct Biologics LLC A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use
CN112955543A (zh) * 2018-06-11 2021-06-11 法国汉氏联合公司(法国H&B) 源自间充质干细胞的细胞外囊泡
US20210290689A1 (en) * 2018-06-29 2021-09-23 North Carolina State University Therapeutic lung repair by inhalation of lung spheroid cell-secreted factors
US20210259969A1 (en) * 2018-07-24 2021-08-26 Mayo Foundation For Medical Education And Research Compositions and methods involving transforming extracellular vesicles
WO2020030817A1 (en) 2018-08-10 2020-02-13 Omnispirant Limited Extracellular vesicles for inhalation
WO2020102684A1 (en) * 2018-11-15 2020-05-22 Washington University Stem cell-derived extracellular vesicles and methods of use thereof
IL320107A (en) 2019-02-07 2025-06-01 Direct Biologics Llc Method for treating osteoarthritis with a combination of mesenchymal stem cell exosomes, synovial mesencymal stem cells, and scaffolds
AU2020228303B2 (en) * 2019-02-28 2025-09-18 Merakris Therapeutics Llc Amniotic fluid-derived extracellular vesicles and uses thereof for wound healing
JP7372518B2 (ja) * 2019-06-27 2023-11-01 国立大学法人山口大学 骨髄由来間葉系幹細胞の培養方法
WO2021011935A1 (en) 2019-07-18 2021-01-21 Direct Biologics, Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
CN114269358A (zh) * 2019-07-31 2022-04-01 上海圣特佳健康科技发展有限公司 针对纤维化、炎症、和/或老化疾病的治疗药物
US20210052641A1 (en) * 2019-08-23 2021-02-25 United Therapeutics Corporation Pre-conditioned extracellular vesicles and methods of production
CN110777113B (zh) * 2019-09-10 2021-09-24 中山大学 一种用于日本血吸虫感染治疗的间质干细胞处理方法
US20210169939A1 (en) * 2019-12-04 2021-06-10 United Therapeutics Corporation Extracellular vesicles and their uses
CN113384597A (zh) * 2020-03-13 2021-09-14 西比曼生物科技（上海）有限公司 含人体细胞衍生的细胞膜外囊泡的雾化吸入制剂、制法及其应用
CN111346110A (zh) * 2020-03-17 2020-06-30 遵义医学院附属医院 间充质干细胞上清液在制备治疗肺细胞损伤制剂中的应用
MX2022013301A (es) 2020-04-22 2023-02-14 Direct Biologics Llc Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa.
MX2023000226A (es) * 2020-07-09 2023-02-23 Exo Biologics Sa Proceso para la fabricacion de vesiculas extracelulares asociadas a proteinas.
EP4178591A1 (en) 2020-07-09 2023-05-17 Exo Biologics Sa Extracellular vesicles and compositions thereof
EP4181935A1 (en) * 2020-07-20 2023-05-24 Brainstorm Cell Therapeutics Ltd. Methods and compositions for treating lung conditions
CN112007049A (zh) * 2020-09-21 2020-12-01 济南磐升生物技术有限公司 一种用于治疗膝骨关节炎的干细胞外泌体组合物
CN112043686A (zh) * 2020-09-21 2020-12-08 沈阳三禾生物科技有限公司 脐带间充质干细胞外泌体雾化液在制备治疗哮喘产品中的应用
EP3995130A1 (en) * 2020-11-06 2022-05-11 JunctuCell Biomed Manufacturing GmbH A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
US20230414730A1 (en) * 2020-11-06 2023-12-28 Aatec Medical Gmbh A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
WO2022114730A2 (ko) * 2020-11-26 2022-06-02 사회복지법인 삼성생명공익재단 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 감염성 질환 치료용 조성물
USD1046870S1 (en) 2020-12-08 2024-10-15 Samsung Electronics Co., Ltd. Accessory panel for television receiver
CN112675203A (zh) * 2021-02-08 2021-04-20 瑞太生物科技(沈阳)有限公司 一种细胞来源的外泌体在制备治疗哮喘和/或肺纤维化生物制剂中的应用
EP4402250A1 (en) 2021-09-16 2024-07-24 Life Technologies Corporation Cell expansion methods and compositions for use therein
CN118973591A (zh) 2022-03-28 2024-11-15 合同会社博子科技 包含miR-140的药物组合物及其制备方法
CN115725499B (zh) * 2022-08-15 2025-08-15 哈尔滨医科大学 一种人脐带间充质干细胞膜仿生纳米囊泡的制备方法和应用
CN116897887A (zh) * 2023-07-31 2023-10-20 湖南中医药大学 一种病毒性哮喘动物模型的构建方法
WO2025226276A1 (en) 2024-04-25 2025-10-30 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles
WO2025250774A1 (en) * 2024-05-31 2025-12-04 Leksum LLC Extracellular vesicles for therapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
FR2766205B1 (fr) * 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US20030221199A1 (en) * 1998-10-20 2003-11-27 Whitsett Jeffrey A. Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
US8021847B2 (en) 2004-06-02 2011-09-20 Proxy Life Science Holdings, Inc. Microvesicle-based compositions and methods
US8337815B2 (en) 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
US20060286089A1 (en) 2005-04-08 2006-12-21 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
WO2008020815A1 (en) 2006-08-15 2008-02-21 Agency For Science, Technology And Research Mesenchymal stem cell conditioned medium
WO2007027157A1 (en) 2005-09-02 2007-03-08 Agency For Science, Technology And Research Method of deriving progenitor cell line
US20090274665A1 (en) * 2006-04-27 2009-11-05 Cell Therapy Technologies, Inc. Stem Cells For Treating Lung Diseases
PL2578081T3 (pl) * 2006-10-11 2016-09-30 Kompozycje, sposoby i urządzenia do leczenia chorób wątroby
PT2254586E (pt) 2008-02-22 2015-05-18 Agency Science Tech & Res Partículas de células estaminais mesenquimais
US20120107413A1 (en) 2009-07-23 2012-05-03 Singapore Health Services Pte Ltd Pre-natal mesenchymal stem cells
CN102858997B (zh) 2009-11-02 2014-06-18 新加坡科技研究局 用于监测细胞状态和用于永生间充质干细胞的方法
KR101189655B1 (ko) * 2010-06-30 2012-10-11 성균관대학교산학협력단 줄기세포 배양액을 포함하는 폐질환 치료용 조성물
CN101890050B (zh) * 2010-07-14 2012-07-04 江苏大学 脐带间质干细胞来源膜性囊泡及其应用
EP2603592A2 (en) 2010-08-13 2013-06-19 The University Court of the University of Glasgow Therapeutic uses of microvesicles and related micrornas
JP2014507160A (ja) 2011-02-22 2014-03-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 循環バイオマーカー
KR102063069B1 (ko) * 2011-03-11 2020-01-08 칠드런'즈 메디컬 센터 코포레이션 중간엽 줄기 세포 엑소솜에 관련된 방법 및 조성물
EP3470073A1 (en) 2012-04-03 2019-04-17 Reneuron Limited Stem cell microparticles
DK3145493T3 (da) 2014-05-18 2022-10-31 Childrens Medical Center Fremgangsmåder og sammensætninger vedrørende exosomer

Also Published As

Publication number Publication date
WO2012125471A1 (en) 2012-09-20
KR20140024310A (ko) 2014-02-28
WO2012125471A9 (en) 2012-11-08
JP2018030845A (ja) 2018-03-01
US9901600B2 (en) 2018-02-27
KR20190018536A (ko) 2019-02-22
EP2683389B1 (en) 2017-05-03
JP2014507482A (ja) 2014-03-27
CA2829586A1 (en) 2012-09-20
CN103648509A (zh) 2014-03-19
KR101947699B1 (ko) 2019-02-14
ES2629502T3 (es) 2017-08-10
CN109432126A (zh) 2019-03-08
US20180221412A1 (en) 2018-08-09
US20220096560A1 (en) 2022-03-31
KR102063069B1 (ko) 2020-01-08
JP6524162B2 (ja) 2019-06-05
CN109432126B (zh) 2022-06-14
JP6204830B2 (ja) 2017-09-27
EP2683389A1 (en) 2014-01-15
CN103648509B (zh) 2019-02-22
US20140065240A1 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
US20220096560A1 (en) Methods and compositions relating to mesenchymal stem cell exosomes
US11759481B2 (en) Methods and compositions relating to exosomes
EP3027738B1 (en) Mscs in the treatment of inflammatory pulmonary diseases
JP2024120900A (ja) 精製された間葉系幹細胞エキソソームおよびその使用
CN115066491A (zh) 细胞外囊泡及其用途
Guo et al. Mesenchymal stem cells reprogram host macrophages to attenuate obliterative bronchiolitis in murine orthotopic tracheal transplantation
US20230141224A1 (en) Fibroblast mediated expansion and augmentation of immune regulatory cells for treatment of acute respiratory distress syndrome (ards)
Bisaccia Study of the mechanism of action of extracellular vesicles derived from umbilical cord stromal cells in a rat model of bronchopulmonary dysplasia: focus on oxidative stress and fibrosis processes.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170228

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250402

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250403